1-amino-3-(phosphonomethylene)cyclobutane-1-carboxylic acid, also known as **(1S,3S)-1-amino-3-(phosphonomethyl)cyclobutane-1-carboxylic acid** or simply **phosphono-γ-aminobutyric acid** (**PγAB**), is a unique and powerful amino acid analog that has garnered considerable attention in research.
Here's why it's important:
**1. Structural Novelty:**
* PγAB is a **non-natural amino acid** that incorporates a phosphonate group (PO3H2), which is rarely found in naturally occurring amino acids.
* This unusual structure makes it an excellent tool for studying the effects of phosphonates on biological processes.
**2. GABA Analog:**
* It is structurally similar to **γ-aminobutyric acid (GABA)**, a major inhibitory neurotransmitter in the brain. This similarity allows PγAB to act as a **GABA analog**, potentially affecting neurotransmission.
**3. Potential Therapeutic Applications:**
* Due to its GABA analog properties, PγAB has been explored for its potential to:
* **Treat neurological disorders:** Research suggests that PγAB might be helpful in managing epilepsy, anxiety disorders, and Parkinson's disease.
* **Enhance cognition:** PγAB's impact on GABAergic signaling could potentially improve cognitive function.
* **Fight cancer:** PγAB has shown promise in inhibiting tumor growth and promoting apoptosis (programmed cell death) in certain cancer cells.
**4. Research Tool:**
* As a non-natural amino acid, PγAB is valuable in various research applications:
* **Probe protein-ligand interactions:** Its unique structure allows researchers to study how proteins interact with phosphonate-containing molecules.
* **Develop new pharmaceuticals:** PγAB's structural characteristics can be used as a template for designing novel drugs with improved therapeutic effects.
**5. Ongoing Research:**
* The research on PγAB is still ongoing, with ongoing efforts to:
* Understand its precise mechanism of action in different biological systems.
* Develop safe and effective therapeutic strategies based on PγAB.
* Explore its potential applications beyond its known uses.
**Key Takeaways:**
* 1-amino-3-(phosphonomethylene)cyclobutane-1-carboxylic acid (PγAB) is a unique and important non-natural amino acid analog.
* Its structural similarity to GABA and its phosphonate group make it a valuable tool for investigating various biological processes.
* PγAB holds potential for therapeutic applications, particularly in neurological disorders and cancer treatment.
* Ongoing research continues to explore its full potential and develop its applications.
1-amino-3-(phosphonomethylene)cyclobutane-1-carboxylic acid: potently inhibits evoked field potentials in the rat lateral perforant path; structure given in first source
ID Source | ID |
---|---|
PubMed CID | 126582 |
CHEMBL ID | 22136 |
SCHEMBL ID | 7820968 |
MeSH ID | M0202831 |
Synonym |
---|
cyclobutylene ap5 |
bdbm50089105 |
1-amino-3-phosphonomethylene-cyclobutanecarboxylic acid |
CHEMBL22136 , |
1-amino-3-(phosphonomethylidene)cyclobutane-1-carboxylic acid |
cyclobutanecarboxylic acid, 1-amino-3-(phsophonomethylene)-, (+-)- |
(+-)-1-amino-3-(phsophonomethylene)cyclobutanecarboxylic acid |
140480-88-2 |
1-amino-3-(phosphonomethylene)cyclobutane-1-carboxylic acid |
SCHEMBL7820968 |
PD075299 |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Metabotropic glutamate receptor 4 | Rattus norvegicus (Norway rat) | EC50 (µMol) | 4.5000 | 0.0090 | 2.5440 | 9.4900 | AID109469 |
Metabotropic glutamate receptor 4 | Homo sapiens (human) | EC50 (µMol) | 4.4000 | 0.0040 | 1.7193 | 9.8000 | AID109331 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
adenylate cyclase-inhibiting G protein-coupled glutamate receptor signaling pathway | Metabotropic glutamate receptor 4 | Homo sapiens (human) |
chemical synaptic transmission | Metabotropic glutamate receptor 4 | Homo sapiens (human) |
neurotransmitter secretion | Metabotropic glutamate receptor 4 | Homo sapiens (human) |
positive regulation of MAPK cascade | Metabotropic glutamate receptor 4 | Homo sapiens (human) |
regulation of neuron apoptotic process | Metabotropic glutamate receptor 4 | Homo sapiens (human) |
regulation of synaptic transmission, glutamatergic | Metabotropic glutamate receptor 4 | Homo sapiens (human) |
G protein-coupled glutamate receptor signaling pathway | Metabotropic glutamate receptor 4 | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
G protein-coupled receptor activity | Metabotropic glutamate receptor 4 | Homo sapiens (human) |
glutamate receptor activity | Metabotropic glutamate receptor 4 | Homo sapiens (human) |
adenylate cyclase inhibiting G protein-coupled glutamate receptor activity | Metabotropic glutamate receptor 4 | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
plasma membrane | Metabotropic glutamate receptor 4 | Rattus norvegicus (Norway rat) |
plasma membrane | Metabotropic glutamate receptor 4 | Homo sapiens (human) |
cytoplasmic vesicle | Metabotropic glutamate receptor 4 | Homo sapiens (human) |
presynapse | Metabotropic glutamate receptor 4 | Homo sapiens (human) |
plasma membrane | Metabotropic glutamate receptor 4 | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID92184 | Antagonistic activity against 5 uM of quis/AMPA at the concentration of 100 uM | 1990 | Journal of medicinal chemistry, Oct, Volume: 33, Issue:10 | Synthesis and activity of a potent N-methyl-D-aspartic acid agonist, trans-1-aminocyclobutane-1,3-dicarboxylic acid, and related phosphonic and carboxylic acids. |
AID93413 | Antagonistic activity against Ionotropic glutamate receptor kainate at the concentration of 100 uM | 1990 | Journal of medicinal chemistry, Oct, Volume: 33, Issue:10 | Synthesis and activity of a potent N-methyl-D-aspartic acid agonist, trans-1-aminocyclobutane-1,3-dicarboxylic acid, and related phosphonic and carboxylic acids. |
AID109469 | Effective concentration against rat Metabotropic glutamate receptor 4 | 2000 | Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11 | (+)-4-phosphonophenylglycine (PPG) a new group III selective metabotropic glutamate receptor agonist. |
AID144188 | Antagonistic activity against 10 uM of N-methyl-D-aspartate glutamate receptor at the concentration of 100 uM | 1990 | Journal of medicinal chemistry, Oct, Volume: 33, Issue:10 | Synthesis and activity of a potent N-methyl-D-aspartic acid agonist, trans-1-aminocyclobutane-1,3-dicarboxylic acid, and related phosphonic and carboxylic acids. |
AID109331 | Agonistic activity at Metabotropic glutamate receptor 4 expressed in mammalian cells by GTPgammaS binding assay | 2000 | Bioorganic & medicinal chemistry letters, Jul-03, Volume: 10, Issue:13 | Synthesis, molecular modeling and preliminary biological evaluation of 1-amino-3-phosphono-3-cyclopentene-1-carboxylic acid and 1-amino-3-phosphono-2-cyclopentene-1-carboxylic acid, two novel agonists of metabotropic glutamate receptors of group III. |
AID144194 | Depression of depolarizing response vs 10 uM N-methyl-D-aspartate glutamate receptor at the concentration of 500 uM; inactive | 1990 | Journal of medicinal chemistry, Oct, Volume: 33, Issue:10 | Synthesis and activity of a potent N-methyl-D-aspartic acid agonist, trans-1-aminocyclobutane-1,3-dicarboxylic acid, and related phosphonic and carboxylic acids. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (50.00) | 18.2507 |
2000's | 3 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.24) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |